298 related articles for article (PubMed ID: 18710439)
21. Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat.
Abraham P; Rabi S
Cancer Chemother Pharmacol; 2009 Jul; 64(2):279-85. PubMed ID: 19015854
[TBL] [Abstract][Full Text] [Related]
22. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
23. Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats.
Görür S; Celik S; Hakverdi S; Aslantaş O; Erdoğan S; Aydin M; Ocak S; Namik Kiper A
Urology; 2008 Oct; 72(4):743-8. PubMed ID: 18554698
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation.
Vera PL; Wang X; Meyer-Siegler KL
Exp Biol Med (Maywood); 2008 May; 233(5):620-6. PubMed ID: 18375833
[TBL] [Abstract][Full Text] [Related]
25. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder.
Jang J; Park EY; Seo SI; Hwang TK; Kim JC
BJU Int; 2006 Aug; 98(2):435-9. PubMed ID: 16879691
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
27. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Harada D; Tsukumo Y; Takashima Y; Manabe H
Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Turner CR; Esser KM; Wheeldon EB
Circ Shock; 1993 Mar; 39(3):237-45. PubMed ID: 8384094
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of lipoic acid and mesna on cyclophosphamide-induced haemorrhagic cystitis in mice.
Song J; Liu L; Li L; Liu J; Song E; Song Y
Cell Biochem Funct; 2014 Mar; 32(2):125-32. PubMed ID: 23650119
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic intravesical instillation of epinephrine prevents cyclophosphamide-induced hemorrhagic cystitis in rats.
Chow YC; Yang S; Huang CJ; Tzen CY; Su YH; Wang PS
Exp Biol Med (Maywood); 2007 Apr; 232(4):565-70. PubMed ID: 17392493
[TBL] [Abstract][Full Text] [Related]
31. Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation.
Kitta T; Tanaka H; Mitsui T; Moriya K; Nonomura K
BJU Int; 2008 Nov; 102(10):1472-6. PubMed ID: 18410434
[TBL] [Abstract][Full Text] [Related]
32. Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide.
Wang CC; Weng TI; Wu ET; Wu MH; Yang RS; Liu SH
Toxicol Sci; 2013 Jan; 131(1):302-10. PubMed ID: 22961095
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of bilirubin against cyclophosphamide induced hemorrhagic cystitis in rats.
Matsuoka Y; Masuda H; Yokoyama M; Kihara K
J Urol; 2008 Mar; 179(3):1160-6. PubMed ID: 18206168
[TBL] [Abstract][Full Text] [Related]
34. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Harada D; Takada C; Nosaka Y; Takashima Y; Kobayashi K; Takaba K; Manabe H
Int Immunopharmacol; 2009 Jan; 9(1):55-62. PubMed ID: 18854230
[TBL] [Abstract][Full Text] [Related]
35. Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis.
Souza-Fiho MV; Lima MV; Pompeu MM; Ballejo G; Cunha FQ; Ribeiro Rde A
Am J Pathol; 1997 Jan; 150(1):247-56. PubMed ID: 9006340
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of simvastatin in the cyclophosphamide-induced hemorrhagic cystitis in rats.
Dantas AC; Batista-Júnior FF; Macedo LF; Mendes MN; Azevedo IM; Medeiros AC
Acta Cir Bras; 2010 Feb; 25(1):43-6. PubMed ID: 20126887
[TBL] [Abstract][Full Text] [Related]
37. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
[TBL] [Abstract][Full Text] [Related]
38. Functional, histological structure and mastocytes alterations in rat urinary bladders following acute and [corrected] chronic cyclophosphamide treatment.
Juszczak K; Gil K; Wyczolkowski M; Thor PJ
J Physiol Pharmacol; 2010 Aug; 61(4):477-82. PubMed ID: 20814076
[TBL] [Abstract][Full Text] [Related]
39. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
[TBL] [Abstract][Full Text] [Related]
40. Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor.
Rock EM; Benzaquen J; Limebeer CL; Parker LA
Pharmacol Biochem Behav; 2009 Feb; 91(4):537-41. PubMed ID: 18835293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
